TOP - May 2022 Vol 15, No 3
During a presentation at the National Comprehensive Cancer Network 2022 Annual Conference, Genevieve Boland, MD, PhD, FACS, Section Head, Melanoma/Sarcoma Surgery; Surgical Director, Termeer Center for Targeted Therapies; and Director, Therapeutic Intralesional Program, Massachusetts General Hospital, Boston, discussed how targeted treatments and immunotherapies are improving the treatment landscape for melanoma.
The International Cholangiocarcinoma Research Network (ICRN) is a program initiated by the Cholangiocarcinoma Foundation (CCF). The core mission of this network of international experts is “to rapidly translate scientific discoveries into practice for cholangiocarcinoma patients through a collaborative, highly translational international research network.”
During the 2022 Cholangiocarcinoma Foundation annual meeting, Lipika Goyal, MD, MPhil, Assistant Professor of Medicine, Harvard Medical School, and Lead, Liver Cancer Research Program, Massachusetts General Hospital Cancer Center, Boston, presented a clinical update on emerging systemic therapies in cholangiocarcinoma (CCA).
With better insights into the biology of cancer and other diseases, genetic medicine is entering “a whole new ballgame,” said Scott Gottlieb, MD, Former FDA Commissioner, during the keynote session at the 11th Annual Summit of the Association for Value-Based Cancer Care in 2021.
A panel moderated by Barbara McAneny, MD, Chief Executive Officer, New Mexico Oncology Hematology Consultants, Albuquerque, at the 11th Annual Summit of the Association for Value-Based Cancer Care in 2021 explored the road ahead for community practices in terms of balancing value and delivering optimal access to care for patients.
Alum Irrigation, a Standard of Care, Is Once Again Readily Available for the Treatment of Hemorrhagic Cystitis
On June 1, 2008, the United States Pharmacopeia (USP) General Chapter 797 Pharmaceutical Compounding – Sterile Compounding (USP ) was made official.
Biosimilars provide more options for care at a lower cost for patients, but due to Medicare’s perverse incentives, many pharmacy benefit managers and health plans have been slow to prioritize biosimilars, leaving savings on the table.
Page 2 of 2
Results 11 - 17 of 17
Results 11 - 17 of 17